BRUKINSA 160 MG
ZANUBRUTINIB : 160 MG · DIN 02554267 · BEIGENE SWITZERLAND GMBH
Health Canada status: MARKETED
What is BRUKINSA?
BRUKINSA 160 MG contains ZANUBRUTINIB : 160 MG. It is listed in the Health Canada Drug Product Database under DIN 02554267, held by BEIGENE SWITZERLAND GMBH, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Nov-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BRUKINSA used for?
BRUKINSA (zanubrutinib) is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM), mantle cell lymphoma (MCL) who have received at least one prior therapy, marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy, and chronic lymphocytic leukemia (CLL). It is also indicated in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) who have received at least 2 prior systemic therapies.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02554267 |
|---|---|
| Brand name | BRUKINSA |
| Generic / active ingredient | ZANUBRUTINIB : 160 MG |
| Manufacturer | BEIGENE SWITZERLAND GMBH |
| Strength | 160 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EL03 ZANUBRUTINIB |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Nov-2025 |
How is it stored and handled?
null
How is it supplied?
Capsules: 120 capsules in a white HDPE plastic bottle. Tablets: 60 tablets in white HDPE bottles.
What can be used instead?
Other Canadian products sharing ATC code L01EL03 ZANUBRUTINIB. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BRUKINSA | 80 MG | CAPSULE | BEIGENE SWITZERLAND GMBH | MARKETED | DIN 02512963 |
Who else supplies ZANUBRUTINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ZANUBRUTINIB appears in 16 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.